SAGE Therapeutics (SAGE) Misses Q1 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
SAGE Therapeutics Announces SAGE-547 Progress and First Quarter 2015 Financial Results
May 14, 2015 6:30 AM EDTSAGE-547 Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in SRSE
Conference Call Scheduled Today at 8:30 a.m. ET
CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today reported business highlights and financial results for the first quarter ended March 31, 2015.
"This year has been transformational for SAGE. We continue to advance the development of our new medicines for CNS disorders where there are... More
SAGE Therapeutics Announces SAGE-547 Progress and First Quarter 2015 Financial Results
May 14, 2015 6:30 AM EDTSAGE-547 Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in SRSE
Conference Call Scheduled Today at 8:30 a.m. ET
CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today reported business highlights and financial results for the first quarter ended March 31, 2015.
"This year has been transformational for SAGE. We continue to advance the development of our new medicines for CNS disorders where there are... More
SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus
May 14, 2015 6:15 AM EDTSAGE-547 Demonstrates Favorable Tolerability
Pharmacodynamic Activity Corroborated by Continuous EEG Findings
Phase 3 STATUS Trial Expected to Initiate by Mid-2015
Conference Call Scheduled Today at 8:30 a.m. ET
CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq: SAGE) today announced that SAGE-547 demonstrated robust activity, with a 77 percent response rate in evaluable patients with super-refractory status epilepticus (SRSE), in a successfully completed Phase 1/2 clinical trial. SAGE-547 also demonstrated favorable tolerability and a benefit-risk profile... More
SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus
May 14, 2015 6:15 AM EDTSAGE-547 Demonstrates Favorable Tolerability
Pharmacodynamic Activity Corroborated by Continuous EEG Findings
Phase 3 STATUS Trial Expected to Initiate by Mid-2015
Conference Call Scheduled Today at 8:30 a.m. ET
CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq: SAGE) today announced that SAGE-547 demonstrated robust activity, with a 77 percent response rate in evaluable patients with super-refractory status epilepticus (SRSE), in a successfully completed Phase 1/2 clinical trial. SAGE-547 also demonstrated favorable tolerability and a benefit-risk profile... More
